Exploring SGLT2 Inhibitor Benefits in Chronic Kidney Disease


Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, and Natalie Bellini, DNP, FNP:-BC, interview Dr Robert Busch, to explore the advantages of SGLT2 inhibitors in chronic kidney disease, cardiovascular health, and their potential to improve overall patient outcomes.

1:21 Treatment landscape for CKD

3:42 Prevalence of CKD in people with diabetes

5:25 Mechanism of SGLT2 inhibitors

8:05 Benefits of SGLT2 inhibitors in non-diabetic patients

9:02 Cardiovascular benefits of SGLT2 inhibitors

11:24 Comparative efficacy of SGLT1,2 inhibitors

13:54 Impact of SGLT2 inhibitors on diabetes

16:50 Adverse effects of SGLT2 inhibitors

20:30 Effect of SGLT2 inhibitors in euglycemic DKA

23:08 Combining SGLT2 inhibitors with other diabetes medications

28:14 Combining finerenone with SGLT2 inhibitors

Related Videos
Kaitlin Mayne, MBChB | Credit X.com
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
Fadi Fakhouri, MD, PhD | Credit: University of Lausanne
Helen Colhoun, MD | Credit: University of Edinburgh
Digital illustration of kidneys | Credit: Fotolia
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Jonathan Barratt, MD | Credit: IgA Nephropathy Foundation
© 2024 MJH Life Sciences

All rights reserved.